Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed a Form 8-K on January 11, 2010, reporting key financial and operational updates as of December 31, 2009. The company provided preliminary estimates for its 2009 net loss, cash position, outstanding shares, and convertible notes. This filing serves to inform investors of Vertex's financial standing at the close of the fiscal year. While specific figures for the net loss are not detailed within the 8-K itself, the press release referenced as Exhibit 99.1 contains these estimated results. Investors can look to this press release for detailed performance metrics and a snapshot of the company's capitalization, which are crucial for understanding its financial health and forward-looking prospects.
Key Highlights
- 1Vertex Pharmaceuticals filed a Form 8-K on January 11, 2010, reporting preliminary financial data.
- 2The report includes estimated 2009 net loss figures.
- 3It provides an estimated balance of cash, cash equivalents, and marketable securities as of December 31, 2009.
- 4Outstanding shares of capital stock as of December 31, 2009, are reported.
- 5The principal amount of convertible subordinated notes outstanding as of December 31, 2009, is disclosed.
- 6The information was disseminated via a press release dated January 10, 2010, attached as Exhibit 99.1.
- 7This 8-K is primarily an informational filing, referencing external data rather than providing detailed financial statements within the report itself.